PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy. [PDF]
Chen R, Li Y, Liang D, Liu J, Sun T.
europepmc +1 more source
Deep vein thrombosis and prostatectomy [PDF]
Keith N. Van Arsdalen+4 more
openalex +1 more source
Controversies in metastatic hormone‐sensitive prostate cancer
Abstract Metastatic hormone‐sensitive prostate cancer (mHSPC) is an incurable phase of prostate cancer. Diagnostic tools and management strategies for this complex disease are expanding. Despite these advances, more therapies may not be the optimal approach for all patients. This review explores four major controversies surrounding mHSPC management—the
Irene Tsung+2 more
wiley +1 more source
Editorial comment: Is 23-h discharge following robotic radical prostatectomy and partial nephrectomy feasible and safe in a quaternary care centre in a developing country? [PDF]
Bhattu AS.
europepmc +1 more source
Artificial intelligence across the cancer care continuum
Abstract Artificial intelligence (AI) holds significant potential to enhance various aspects of oncology, spanning the cancer care continuum. This review provides an overview of current and emerging AI applications, from risk assessment and early detection to treatment and supportive care.
Irbaz Bin Riaz+2 more
wiley +1 more source
Sensitivity analysis for time-to-event data accounting for intra-individual variability in time-varying covariates with missing data. [PDF]
Liaqat M+5 more
europepmc +1 more source
The carbon footprint of transperineal prostate biopsy
Abstract Objective To evaluate the carbon footprint of transperineal prostate biopsy (TPPB). Climate change is the biggest global public health threat of the 21st century. Healthcare contributes 5% to global greenhouse gas emissions. Despite growing enthusiasm for sustainable urology, there is little data on the environmental impact of urological ...
Daniel A. Carson+5 more
wiley +1 more source
The role of radiotherapy in pelvic nodal recurrence following definitive treatment for prostate cancer. [PDF]
Dematteis A+5 more
europepmc +1 more source